Akebia Ther Return On Tangible Assets Over Time
| AKBA Stock | USD 2.06 0.01 0.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Akebia Ther Performance and Akebia Ther Correlation. Akebia |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share 0.834 | Quarterly Revenue Growth (0.11) | Return On Assets (0.09) | Return On Equity (5.53) |
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Return On Tangible Assets Analysis
Compare Akebia Ther and related stocks such as Protalix Biotherapeutics, Cidara Therapeutics, and X4 Pharmaceuticals Return On Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX | 0.0179 | (0.7051) | (0.1476) | (0.2452) | (0.3816) | 0.5968 | (0.357) | (1.1809) | (0.4328) | (0.5781) | (0.2192) | (0.4613) | (0.2676) | 0.0984 | 0.1 |
| CDTX | (6.6866) | (6.6866) | (6.6866) | (6.6866) | (0.4885) | (0.2927) | (0.4503) | (0.7051) | (0.746) | (0.5811) | (1.1978) | (0.5829) | (0.6261) | (0.3421) | (0.36) |
| XFOR | (1.3899) | (1.3899) | (1.3899) | (1.3899) | (1.3899) | (1.3899) | (3.0214) | (0.4169) | (1.1949) | (0.4237) | (0.6488) | (0.8885) | (0.679) | (0.7788) | (0.82) |
| MCRB | (0.4781) | (0.4781) | (0.4781) | (2.8715) | (0.1424) | (0.2526) | (0.3359) | (0.4716) | (0.8213) | (0.4851) | (0.2521) | (0.1733) | (0.7277) | (0.3171) | (0.33) |
| OCEA | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (4.2824) | (789) | 0.0051 | 0.0046 | 0.0048 |
| ENVB | (0.5217) | (1.4869) | (4.3966) | (0.036) | (6.6163) | (0.2608) | (0.2037) | (0.4357) | (1.6681) | (0.7286) | (2.8023) | (2.6899) | (0.9634) | (0.0042) | (0.0044) |
| ELEV | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (3.0731) | (0.2134) | (0.2143) | (1.0098) | (0.513) | (0.54) |
| HEPA | (9.721) | (9.721) | (9.721) | (2.6392) | (2.6683) | (2.1127) | (1.1176) | (1.6012) | (3.0206) | (0.4525) | (0.467) | (0.3322) | (0.7396) | (2.7039) | (2.84) |
Akebia Ther and related stocks such as Protalix Biotherapeutics, Cidara Therapeutics, and X4 Pharmaceuticals Return On Tangible Assets description
A profitability metric that measures a company's ability to generate earnings from its tangible assets.My Equities
My Current Equities and Potential Positions
| Akebia Ther | AKBA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.06
Check out Akebia Ther Performance and Akebia Ther Correlation. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Akebia Ther technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.